GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization (WHO) since 2018 as a preferred treatment for the viru...

The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a roller-coaster ride. And there’s still more loops to negotiate. On...

After suffering setbacks in the clinic and in court over the last week, Bayer’s ability to overhaul its corporate structure is becoming more constricted, one group o...

While Indianapolis-based Eli Lilly has criticized moves by Indiana's Republican lawmakers and leaders over the years, the company's CEO is backing the president...

News of the Federal Trade Commission (FTC) lawsuit challenging Amgen’s $28 billion buyout of Horizon prompted an immediate question: Will the U.S. antitrust enforcer...

Hundreds of manufacturing jobs are in limbo as Sanofi weighs operations at a pair of vaccine plants overseas, marking the latest in an onslaught of job cuts across th...

Ionis Pharmaceuticals will soon have some new manufacturing digs to help produce its wide range of pipeline meds. Wednesday, the company unveiled plans for a n...

For COVID-19 antibody drugs in the pandemic world, it’s been life in the fast lane. With the coronavirus rapidly evolving, there is little longevity for finely tuned...

As Sanofi prepares to release third-quarter results—after a tough summer for its share price—the company says it expects a major boost from exchange rate changes. ...

Reports of dwindling COVID-19 vaccine demand have been circulating for months. Now, the slump threatens to cut into BioNTech's revenue hauls in 2022 and beyond, accor...